News & Events about Curis Inc.
StockNews.com began coverage on shares of Curis (NASDAQ:CRIS Get Rating) in a research note published on Thursday. The brokerage issued a hold rating on the biotechnology companys stock. Other equities analysts also recently issued reports about the company. HC Wainwright cut their target price on ...
StockNews.com began coverage on shares of Curis (NASDAQ:CRIS Get Rating) in a research note published on Thursday. The brokerage issued a hold rating on the biotechnology companys stock. Other equities analysts also recently issued reports about the company. HC Wainwright cut their ...
Curis Announces Additional Encouraging Clinical Data from TakeAim Leukemia Study of emavusertib (CA-4948) in Monotherapy R/R AML and hrMDS Curis Announces Additional Encouraging Clinical Data from TakeAim Leukemia Study of emavusertib (CA-4948) in Monotherapy R/R AML and hrMDS PR Newswire...
Curis to Host Webcast to Discuss Updated Emavusertib Clinical Data in Leukemia Curis to Host Webcast to Discuss Updated Emavusertib Clinical Data in Leukemia PR Newswire LEXINGTON, Mass., Dec. 5, 2022 Curis to review results during conference call, featuring commentaryby Dr. Eric Winer, M.D...
Curis Announces Date for the 2nd Annual VISTA Symposium Curis Announces Date for the 2nd Annual VISTA Symposium PR Newswire LEXINGTON, Mass., Sept. 19, 2022 Industry experts in immuno-oncology will gather to discuss VISTA on September 23, 2022 Symposium hosted by Randolph Noelle, Ph.D. LEXINGTON...